Resources to Improve the Care of Patients With NSCLC and EGFR Mutations (NASP)

Interact with an expert during a 1-hour live meeting examining current best practices and the latest advances in the management of EGFR-mutated NSCLC in the context of a series of patient cases. Register today!


  • Welcome & Introduction
  • Biomarker Testing for EGFR Mutation Status in Newly Diagnosed NSCLC
    • Tissue-based vs blood-based testing
    • Interpreting results to individualize therapy selection
  • Selecting First-line Therapy in EGFR Mutation–Positive Advanced/Metastatic NSCLC
    • Implications on therapy choice of most recent phase III trial data and use of adjuvant EGFR TKI therapy for early-stage disease
    • Examining first-line EGFR TKI–based combination therapy
    • Considerations for special patient populations
  • Acquired Resistance Following Prior EGFR TKI Therapy
    • Mechanisms of resistance to available EGFR TKIs
  • Considerations for Specialty Pharmacy
  • Audience Question & Answer Session


Date / Time
Event Details


Stefanie Houseknecht, PharmD, BCOP

Clinical Pharmacy Specialist
Thoracic Oncology
The Johns Hopkins Hospital and Bayview Medical Center
Baltimore, Maryland

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to optimally integrate current data needed to make treatment decisions and improve outcomes in the EGFR mutation–positive NSCLC patient population.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with EGFR mutation–positive NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC for evaluation of EGFR mutation status in newly diagnosed patients and those with acquired resistance following EGFR TKI therapy
  • Compare available efficacy and safety data of systemic therapies throughout the continuum of EGFR mutation–positive metastatic or locally advanced NSCLC from the first-line setting to the second-line setting and beyond (including outcomes by type of EGFR mutation and the presence of co-mutations)
  • Describe the biologic rationale for the design of clinical trials combining EGFR-targeted and VEGFR-targeted therapy in EGFR mutation–positive NSCLC and potential ramifications for practice based on recent clinical trial results
  • Plan therapy based on an understanding of the subtype of EGFR mutation as well as co-mutations such as TP53
  • Refine EGFR mutation–positive metastatic and locally advanced NSCLC treatment algorithms based on molecular profile and prior therapy exposure in earlier lines of therapy
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for EGFR mutation–positive NSCLC


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ProCE, LLC. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-22-204-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) and ProCE, LLC require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and ProCE policy. CCO and ProCE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.